ADIPOQ and metastatic neoplasm: Focusing on cancer-related risk factors associated with poor prognoses, such as obesity-related diseases and on their molecular pathways [8,45,46] (i.e., increasing adiponectin levels using adiponectin analogs, targeting specific PPAR-signaling), can potentially become an innovative personalized treatment for breast cancer patients and metastatic disease in improving the metabolic state and, therefore, response to systemic therapies, locoregional surgery, and overall survival.